Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could offer a promising advancement for obesity loss . Preliminary patient tests have indicated substantial decreases in body mass , potentially surpassing current weight-loss treatments. Despite this, further stud